医学
痴呆
危险系数
内科学
2型糖尿病
入射(几何)
随机对照试验
队列
利拉鲁肽
临床试验
安慰剂
糖尿病
疾病
置信区间
内分泌学
病理
替代医学
物理
光学
作者
Caroline Holm Nørgaard,Sarah Friedrich,Charlotte T. Hansen,Thomas Alexander Gerds,Clive Ballard,Daniél Vega Møller,Lotte Bjerre Knudsen,Kajsa Kvist,Bernard Zinman,Ellen Holm,Christian Torp‐Pedersen,Lina Steinrud Mørch
摘要
People with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes.We assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients).Dementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs).Treatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI